Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

David Miles; José Baselga; Dino Amadori; Patrapim Sunpaweravong; Vladimir Semiglazov; Adam Knott; Emma Clark; Graham Ross; Sandra M. Swain

doi:10.1007/s10549-013-2710-z

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

David Miles, José Baselga, Dino Amadori, Patrapim Sunpaweravong, Vladimir Semiglazov, Adam Knott, Emma Clark, Graham Ross, Sandra M. Swain

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conducted by age group (

Original language	English
Pages (from-to)	89-99
Number of pages	11
Journal	Breast Cancer Research and Treatment
Volume	142
Issue number	1
DOIs	https://doi.org/10.1007/s10549-013-2710-z
Publication status	Published - Nov 2013

Keywords

Elderly
HER2
Metastatic breast cancer
Older women
Pertuzumab
Trastuzumab

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s10549-013-2710-z

Fingerprint

Dive into the research topics of 'Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)'. Together they form a unique fingerprint.

Cite this

Miles, D., Baselga, J., Amadori, D., Sunpaweravong, P., Semiglazov, V., Knott, A., Clark, E., Ross, G., & Swain, S. M. (2013). Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Research and Treatment, 142(1), 89-99. https://doi.org/10.1007/s10549-013-2710-z

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel : Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). / Miles, David; Baselga, José; Amadori, Dino et al.

In: Breast Cancer Research and Treatment, Vol. 142, No. 1, 11.2013, p. 89-99.

Research output: Contribution to journal › Article › peer-review

Miles, D, Baselga, J, Amadori, D, Sunpaweravong, P, Semiglazov, V, Knott, A, Clark, E, Ross, G & Swain, SM 2013, 'Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)', Breast Cancer Research and Treatment, vol. 142, no. 1, pp. 89-99. https://doi.org/10.1007/s10549-013-2710-z

Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A et al. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Research and Treatment. 2013 Nov;142(1):89-99. doi: 10.1007/s10549-013-2710-z

@article{2ad7c417776d476ab287b7f8b10dfd99,

title = "Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)",

abstract = "Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conducted by age group (",

keywords = "Elderly, HER2, Metastatic breast cancer, Older women, Pertuzumab, Trastuzumab",

author = "David Miles and Jos{\'e} Baselga and Dino Amadori and Patrapim Sunpaweravong and Vladimir Semiglazov and Adam Knott and Emma Clark and Graham Ross and Swain, {Sandra M.}",

year = "2013",

month = nov,

doi = "10.1007/s10549-013-2710-z",

language = "English",

volume = "142",

pages = "89--99",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York LLC",

number = "1",

}

TY - JOUR

T1 - Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel

T2 - Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

AU - Miles, David

AU - Baselga, José

AU - Amadori, Dino

AU - Sunpaweravong, Patrapim

AU - Semiglazov, Vladimir

AU - Knott, Adam

AU - Clark, Emma

AU - Ross, Graham

AU - Swain, Sandra M.

PY - 2013/11

Y1 - 2013/11

N2 - Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conducted by age group (

AB - Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conducted by age group (

KW - Elderly

KW - HER2

KW - Metastatic breast cancer

KW - Older women

KW - Pertuzumab

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84888228586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888228586&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2710-z

DO - 10.1007/s10549-013-2710-z

M3 - Article

C2 - 24129974

AN - SCOPUS:84888228586

SN - 0167-6806

VL - 142

SP - 89

EP - 99

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this